Amylyx (AMLX) Director Karen Firestone Exercises Options

What Happened

• Karen Firestone, a director of Amylyx Pharmaceuticals (AMLX), exercised option-based derivatives on 2026-08-31. She acquired 25,000 shares at $1.76 ($44,000) and 25,000 shares at $5.05 ($126,250), for total cash outlay of $170,250. The filing also shows two corresponding dispositions of 25,000 shares each at $0.00 (total 50,000 disposed). The acquired and disposed amounts are equal, so the net change in her reported shares from these transactions is zero.
• This was an exercise/conversion of options (transaction code M), not an open-market purchase or sale of company stock.

Key Details

• Transaction date: 2026-08-31; Form 4 filed 2026-09-02 (Accession: 0001193125-26-380152).
• Prices and amounts: 25,000 shares @ $1.76 (acquired) = $44,000; 25,000 shares @ $5.05 (acquired) = $126,250; 25,000 @ $0.00 (disposed) and 25,000 @ $0.00 (disposed).
• Net shares from these entries: 50,000 acquired − 50,000 disposed = 0 net change.
• Shares owned after transaction: Not specified in the provided filing details.
• Footnote: F1 states the option is fully vested and exercisable.
• Disposed-at-$0 entries commonly reflect shares surrendered in settlement or for tax withholding in option exercises (the filing lists them as derivative dispositions); the filing does not show any open-market sale.

Context

• For derivative transactions like this, the key action was exercising options. Because an equal number of shares were disposed at $0.00, this appears to be a non-cash surrender/settlement rather than a market sale; it does not indicate an open-market sell or purchase of additional shares.
• These entries are routine for option exercises and, without additional context on total holdings or subsequent open-market trades, do not by themselves signal a change in insider conviction.